

Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

https://marketpublishers.com/r/AA8BCC7D1E5BEN.html

Date: March 2022

Pages: 186

Price: US\$ 2,000.00 (Single User License)

ID: AA8BCC7D1E5BEN

Abstracts

Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Alopecia (Dermatology) pipeline landscape.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.



The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 15, 10, 1, 32, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).

The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.



The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and



understand from the know-how what drove them from pipeline.



Contents

Introduction

Global Markets Direct Report Coverage

Alopecia - Overview

Alopecia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Alopecia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alopecia - Companies Involved in Therapeutics Development

3SBio Inc

Aclaris Therapeutics Inc

Addpharma Inc

Akaal Pharma Pty Ltd

Alexion Pharmaceuticals Inc

Almirall SA

AnaptysBio Inc

Aneira Pharma Inc

AnTolRx Inc

Applied Biology Inc

Berg LLC

Biolab Sanus Farmaceutica Ltda

BiologicsMD Inc

Bioquark Inc

BirchBioMed Inc

Caregen Co Ltd

Chong Kun Dang Pharmaceutical Corp

CK Regeon Inc

Concert Pharmaceuticals Inc

Cosmo Pharmaceuticals NV

Dermaliq Therapeutics Inc

dNovo Inc



Eli Lilly and Co

Energenesis Biomedical Co Ltd

Equillium Inc

Exicure Inc

Follica Inc.

HapInscience Inc

HCell Inc

HCW Biologics Inc

Hope Medicine Inc

Horizon Therapeutics Plc

Inventage Lab Inc

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

JN Biosciences LLC

Johnson & Johnson

JW Pharmaceutical Corp

Kedi Biomedical Co Ltd

Kintor Pharmaceutical Ltd

Kuhnil Pharmaceutical Co Ltd

LG Chem Ltd

Maxinovel Pharmaceuticals

METiS Pharmaceuticals

Mirae Cell Bio Co Ltd

Nepsone ehf

OliX Pharmaceuticals Inc

Omega Therapeutics Inc

OnQuality Pharmaceuticals LLC

Pfizer Inc

Phio Pharmaceuticals Corp

Ponce Therapeutics Inc

ProTransit Nanotherapy LLC

RiverTown Therapeutics Inc

Samson Clinical Pty Ltd

Shenzhen Chipscreen Biosciences Co Ltd

siRNAgen Therapeutics Corp

Sisaf Ltd

Soterios Ltd

Stemson Therapeutics Corp

Suzhou Zelgen Biopharmaceutical Co Ltd



TagCyx Biotechnologies

Technoderma Medicines Inc

Throne Biotechnologies Inc

Tigo GmbH

Triple Hair Inc

Tritech Biopharmaceuticals Co Ltd

Turn Biotechnologies Inc

VasoDynamics Ltd

Alopecia - Drug Profiles

(cyclosporine A + minoxidil + RT-175) - Drug Profile

Product Description

Mechanism Of Action

AB-101 - Drug Profile

Product Description

Mechanism Of Action

AB-102 - Drug Profile

Product Description

Mechanism Of Action

AB-103 - Drug Profile

Product Description

Mechanism Of Action

AB-105 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AD-106 - Drug Profile

Product Description

Mechanism Of Action

Al-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AKP-11 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ANR-001 - Drug Profile

Product Description

Mechanism Of Action



Antisense RNAi Oligonucleotides for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

ARQ-255 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ATI-501 - Drug Profile

Product Description

Mechanism Of Action

History of Events

baricitinib - Drug Profile

Product Description

Mechanism Of Action

History of Events

BL-3000 - Drug Profile

Product Description

Mechanism Of Action

BMD-1141 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BQ-A - Drug Profile

Product Description

Mechanism Of Action

calcitriol - Drug Profile

Product Description

Mechanism Of Action

History of Events

CB-0311 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cell Therapy for Alopecia - Drug Profile

Product Description

Mechanism Of Action

Cell Therapy for Coronavirus Disease 2019 (COVID-19), Alopecia Areata and Type 1

Diabetes - Drug Profile

Product Description



Mechanism Of Action

History of Events

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

History of Events

CKD-843 - Drug Profile

Product Description

Mechanism Of Action

CKHT-5108 - Drug Profile

Product Description

Mechanism Of Action

crisaborole - Drug Profile

Product Description

Mechanism Of Action

CS-12192 - Drug Profile

Product Description

Mechanism Of Action

CS-12328 - Drug Profile

Product Description

Mechanism Of Action

CU-40101 - Drug Profile

Product Description

Mechanism Of Action

CWL-080061 - Drug Profile

Product Description

Mechanism Of Action

History of Events

daxdilimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

delgocitinib - Drug Profile

Product Description

Mechanism Of Action

History of Events

deuruxolitinib phosphate - Drug Profile

Product Description

Mechanism Of Action



History of Events

DLQ-01 - Drug Profile

Product Description

Mechanism Of Action

Drug for Alopecia Areata - Drug Profile

Product Description

Mechanism Of Action

Drugs to Agonize Aryl Hydrocarbon Receptor for Alopecia, Vitiligo and Pemphigus -

Drug Profile

Product Description

Mechanism Of Action

dutasteride - Drug Profile

Product Description

Mechanism Of Action

History of Events

ENERGIF-701 - Drug Profile

Product Description

Mechanism Of Action

History of Events

EQ-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

etrasimod - Drug Profile

Product Description

Mechanism Of Action

History of Events

finasteride - Drug Profile

Product Description

Mechanism Of Action

History of Events

finasteride LA - Drug Profile

Product Description

Mechanism Of Action

History of Events

GT-20029 - Drug Profile

Product Description

Mechanism Of Action

History of Events



Hair loss - Drug Profile

Product Description

Mechanism Of Action

HC-0100 - Drug Profile

Product Description

Mechanism Of Action

HC-017AA - Drug Profile

Product Description

Mechanism Of Action

History of Events

HCW-9302 - Drug Profile

Product Description

Mechanism Of Action

HMI-115 - Drug Profile

Product Description

Mechanism Of Action

History of Events

HS-301 - Drug Profile

Product Description

Mechanism Of Action

HuABC-2 - Drug Profile

Product Description

Mechanism Of Action

interferon beta-1b - Drug Profile

Product Description

Mechanism Of Action

ivarmacitinib sulfate - Drug Profile

Product Description

Mechanism Of Action

History of Events

jaktinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

KI-1104 - Drug Profile

Product Description

Mechanism Of Action

KI-1105 - Drug Profile

Product Description



Mechanism Of Action

lithium gluconate - Drug Profile

Product Description

Mechanism Of Action

LR-19030 - Drug Profile

Product Description

Mechanism Of Action

Max-3 - Drug Profile

Product Description

Mechanism Of Action

minoxidil - Drug Profile

Product Description

Mechanism Of Action

minoxidil - Drug Profile

Product Description

Mechanism Of Action

History of Events

MN-709 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MTS-003 - Drug Profile

Product Description

Mechanism Of Action

NG-13 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Oligonucleotide to Inhibit SFRP1 for Alopecia - Drug Profile

Product Description

Mechanism Of Action

Oligonucleotides 1 for Androgenic Alopecia - Drug Profile

Product Description

Mechanism Of Action

History of Events

OLX-104C - Drug Profile

Product Description

Mechanism Of Action

History of Events



OQL-071 - Drug Profile

Product Description

Mechanism Of Action

Peptide for Alopecia and Wounds - Drug Profile

Product Description

Mechanism Of Action

Personalized Hair Stem Cells - Drug Profile

Product Description

Mechanism Of Action

Protein to Antagonize PPAR Gamma-2 for Obesity, Alopecia, Osteoporosis and

Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

PT-002mn - Drug Profile

Product Description

Mechanism Of Action

PTN-103A - Drug Profile

Product Description

Mechanism Of Action

History of Events

PTN-103C - Drug Profile

Product Description

Mechanism Of Action

History of Events

pyrilutamide - Drug Profile

Product Description

Mechanism Of Action

History of Events

RCGD-423 - Drug Profile

Product Description

Mechanism Of Action

Recombinant Proteins to Antagonize IFN-Gamma Receptor 1 for Alopecia Areata and

Graft Arteriosclerosis - Drug Profile

Product Description

Mechanism Of Action

ritlecitinib - Drug Profile

Product Description

Mechanism Of Action

History of Events



rosnilimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Samcyprone - Drug Profile

Product Description

Mechanism Of Action

History of Events

SIS-023 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Cardiac Hypertrophy - Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Alopecia - Drug Profile

Product Description

Mechanism Of Action

STS-01 - Drug Profile

Product Description

Mechanism Of Action

TAGX-0003 - Drug Profile

Product Description

Mechanism Of Action

TDM-105795 - Drug Profile

Product Description

Mechanism Of Action

History of Events

tesnatilimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

TH-07 - Drug Profile

Product Description

Mechanism Of Action

TRN-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

UK-5099 - Drug Profile



Product Description

Mechanism Of Action

Alopecia - Dormant Projects

Alopecia - Discontinued Products

Alopecia - Product Development Milestones

Featured News & Press Releases

Mar 26, 2022: Nearly 40% of adults with alopecia areata taking OLUMIANT 4-mg saw at

least 80% scalp hair coverage at 52 weeks in Lilly's pivotal phase 3 studies

Mar 07, 2022: Kintor concludes enrolment of Phase II alopecia trial in China

Mar 06, 2022: Completion of patient enrollment in phase II clinical trial of KX-826 in

China for the treatment of AGA in female patients

Mar 02, 2022: Kintor begins dosing Phase II androgenic alopecia treatment trial in US

Feb 04, 2022: Kintor doses first subject in US Phase I trial of dermatology asset

Feb 03, 2022: Kintor Pharmaceutical: Voluntary announcement first subject dosing in phase I clinical trial of GT20029 (ar-protac) in the United States

priase i clinical that of 0120029 (ai-protac) in the Office States

Jan 25, 2022: Hope Medicine announces US FDA clearance for phase II clinical trial of

a first-in-class monoclonal antibody, HMI-115, in androgen alopecia

Jan 11, 2022: 3SBio announces submission and acceptance of the application for the market launch of 5% Minoxidil foam

Jan 04, 2022: Concert Pharmaceuticals completes enrollment in THRIVE-AA2 phase 3 clinical trial evaluating CTP-543 for Alopecia Areata

Jan 03, 2022: Kintor begins dosing in androgenic alopecia treatment trial in China

Nov 24, 2021: Kintor Pharma receives IND clearance by NMPA for KX-826's pivotal study to treat male alopecia patients

Nov 15, 2021: AnaptysBio announces positive rosnilimab healthy volunteer phase 1 topline data

Nov 12, 2021: Kintor Pharma announces dosing of first patient in phase II clinical trial of KX-826 for the treatment of androgenic alopecia female patients in China

Oct 25, 2021: Concert Pharmaceuticals completes enrollment in THRIVE-AA1 phase 3 clinical trial evaluating CTP-543 for alopecia areata

Sep 30, 2021: OLUMIANT significantly improved hair regrowth to at least 80% scalp coverage as early as 24 weeks across first completed phase 3 studies for alopecia areata

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation



Contact Us Disclaimer



List Of Tables

LIST OF TABLES

Number of Products under Development for Alopecia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Companies, 2022 (Contd..3)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Alopecia - Pipeline by 3SBio Inc, 2022

Alopecia - Pipeline by Aclaris Therapeutics Inc, 2022

Alopecia - Pipeline by Addpharma Inc, 2022

Alopecia - Pipeline by Akaal Pharma Pty Ltd, 2022

Alopecia - Pipeline by Alexion Pharmaceuticals Inc, 2022

Alopecia - Pipeline by Almirall SA, 2022

Alopecia - Pipeline by AnaptysBio Inc, 2022

Alopecia - Pipeline by Aneira Pharma Inc, 2022

Alopecia - Pipeline by AnTolRx Inc, 2022

Alopecia - Pipeline by Applied Biology Inc, 2022

Alopecia - Pipeline by Berg LLC, 2022

Alopecia - Pipeline by Biolab Sanus Farmaceutica Ltda, 2022

Alopecia - Pipeline by BiologicsMD Inc, 2022

Alopecia - Pipeline by Bioquark Inc, 2022

Alopecia - Pipeline by BirchBioMed Inc, 2022

Alopecia - Pipeline by Caregen Co Ltd, 2022

Alopecia - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022



Alopecia - Pipeline by CK Regeon Inc, 2022

Alopecia - Pipeline by Concert Pharmaceuticals Inc, 2022

Alopecia - Pipeline by Cosmo Pharmaceuticals NV, 2022

Alopecia - Pipeline by Dermaliq Therapeutics Inc, 2022

Alopecia - Pipeline by dNovo Inc, 2022

Alopecia - Pipeline by Eli Lilly and Co, 2022

Alopecia - Pipeline by Energenesis Biomedical Co Ltd, 2022

Alopecia - Pipeline by Equillium Inc, 2022

Alopecia - Pipeline by Exicure Inc, 2022

Alopecia - Pipeline by Follica Inc, 2022

Alopecia - Pipeline by Haplnscience Inc, 2022

Alopecia - Pipeline by HCell Inc, 2022

Alopecia - Pipeline by HCW Biologics Inc, 2022

Alopecia - Pipeline by Hope Medicine Inc, 2022

Alopecia - Pipeline by Horizon Therapeutics Plc, 2022

Alopecia - Pipeline by Inventage Lab Inc, 2022

Alopecia - Pipeline by Japan Tobacco Inc, 2022

Alopecia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Alopecia - Pipeline by JN Biosciences LLC, 2022

Alopecia - Pipeline by Johnson & Johnson, 2022

Alopecia - Pipeline by JW Pharmaceutical Corp. 2022

Alopecia - Pipeline by Kedi Biomedical Co Ltd, 2022

Alopecia - Pipeline by Kintor Pharmaceutical Ltd, 2022

Alopecia - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022

Alopecia - Pipeline by LG Chem Ltd, 2022

Alopecia - Pipeline by Maxinovel Pharmaceuticals, 2022

Alopecia - Pipeline by METiS Pharmaceuticals, 2022

Alopecia - Pipeline by Mirae Cell Bio Co Ltd, 2022

Alopecia - Pipeline by Nepsone ehf, 2022

Alopecia - Pipeline by OliX Pharmaceuticals Inc, 2022

Alopecia - Pipeline by Omega Therapeutics Inc, 2022

Alopecia - Pipeline by OnQuality Pharmaceuticals LLC, 2022

Alopecia - Pipeline by Pfizer Inc, 2022

Alopecia - Pipeline by Phio Pharmaceuticals Corp, 2022

Alopecia - Pipeline by Ponce Therapeutics Inc, 2022

Alopecia - Pipeline by ProTransit Nanotherapy LLC, 2022

Alopecia - Pipeline by RiverTown Therapeutics Inc, 2022

Alopecia - Pipeline by Samson Clinical Pty Ltd, 2022

Alopecia - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022



Alopecia - Pipeline by siRNAgen Therapeutics Corp, 2022

Alopecia - Pipeline by Sisaf Ltd, 2022

Alopecia - Pipeline by Soterios Ltd, 2022

Alopecia - Pipeline by Stemson Therapeutics Corp, 2022

Alopecia - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022

Alopecia - Pipeline by TagCyx Biotechnologies, 2022

Alopecia - Pipeline by Technoderma Medicines Inc, 2022

Alopecia - Pipeline by Throne Biotechnologies Inc, 2022

Alopecia - Pipeline by Tigo GmbH, 2022

Alopecia - Pipeline by Triple Hair Inc, 2022

Alopecia - Pipeline by Tritech Biopharmaceuticals Co Ltd, 2022

Alopecia - Pipeline by Turn Biotechnologies Inc, 2022

Alopecia - Pipeline by VasoDynamics Ltd, 2022

Alopecia - Dormant Projects, 2022

Alopecia - Dormant Projects, 2022 (Contd..1)

Alopecia - Dormant Projects, 2022 (Contd..2)

Alopecia - Dormant Projects, 2022 (Contd..3)

Alopecia - Discontinued Products, 2022



List Of Figures

LIST OF FIGURES

Number of Products under Development for Alopecia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022



I would like to order

Product name: Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key

Players, 2022 Update

Product link: https://marketpublishers.com/r/AA8BCC7D1E5BEN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/AA8BCC7D1E5BEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$

